The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts
Year: 2009
Type: article
Abstract: In spite of the progress in the treatment of lysosomal storage diseases (LSDs), in some of these disorders the available therapies show limited efficacy and a need exists to identify novel therapeutic strategies. We studied the combination of enzyme replacement and enzyme enhancement by pharmacological chaperones in Pompe disease (PD), a metabolic myopathy caused by the deficiency of the lysosomal acid alpha-glucosidase. We showed that coincubation of Pompe fibroblasts with recombinant human alpha-glucosidase and the chaperone N-butyldeoxynojirimycin (NB-DNJ) resulted in more efficient correction of enzyme activity. The chaperone improved alpha-glucosidase delivery to lysosomes, enhanced enzyme maturation, and increased enzyme stability. Improved enzyme correction was also found in vivo in a mouse model of PD treated with coadministration of single infusions of recombinant human alpha-glucosidase and oral NB-DNJ. The enhancing effect of chaperones on recombinant enzymes was also observed in fibroblasts from another lysosomal disease, Fabry disease, treated with recombinant alpha-galactosidase A and the specific chaperone 1-deoxygalactonojirimycin (DGJ). These results have important clinical implications, as they demonstrate synergy between pharmacological chaperones and enzyme replacement. A synergistic effect of these treatments may result particularly useful in patients responding poorly to therapy and in tissues in which sufficient enzyme levels are difficult to obtain.
Source: Molecular Therapy
DOI: 10.1038/mt.2009.53
Authors: Caterina Porto, Monica Cardone, Federica Fontana, Barbara Rossi, Maria Rosaria Tuzzi, Antonietta Tarallo, Maria Vittoria Barone, Generoso Andria, Giancarlo Parenti
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Keywords: Pompe disease, N-butyldeoxynojirimycin, pharmacological chaperones, enzyme replacement therapy, lysosomal acid alpha-glucosidase, lysosomal storage disease, enzyme maturation, enzyme stability, Fabry disease, alpha-galactosidase A, 1-deoxygalactonojirimycin, recombinant enzyme therapy, mouse model
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W2084764150
